BIMOSIAMOSE DISODIUM
| 中文名稱 | BIMOSIAMOSE DISODIUM |
|---|---|
| 中文同義詞 | 比莫西糖二鈉鹽;化合物 T14573 |
| 英文名稱 | Bimosiamose disodium |
| 英文同義詞 | Bimosiamose disodium;TBC-1269Z |
| CAS號(hào) | 187269-60-9 |
| 分子式 | C46H52Na2O16 |
| 分子量 | 906.87502 |
| EINECS號(hào) | |
| 相關(guān)類別 | 對(duì)照品 |
| Mol文件 | 187269-60-9.mol |
| 結(jié)構(gòu)式 |  |
BIMOSIAMOSE DISODIUM 性質(zhì)
| 熔點(diǎn) | 243-245° |
|---|
IC50: 88 μM (E-selectin), 20 μM (P-selectin), and 86 μM (L-selectin)
Bimosiamose (TBC-1269) operates by inhibiting neutrophil recruitment to the site of inflammation through blocking the initial rolling phase of recruitment. Bimosiamose (TBC-1269) inhibits cell recruitment and does not possess any cytotoxic effect on neutrophils.
Bimosiamose (TBC-1269; 25 mg/kg; intravenous injection; Sprague-Dawley rats) treatment shows a significant increase in survival. Best overall survival, 70%, is observed when TBC-1269 is administered 15 minutes before reperfusion, and also shows a marked decrease in liver enzyme levels at 6 hours after reperfusion. Neutrophil migration is also significantly ameliorated (81%). The histologic damage scores is also improved.
| Animal Model: | Sprague-Dawley rats (200-225g) with ischemia and reperfusion (I/R) |
| Dosage: | 25 mg/kg |
| Administration: | Intravenous injection |
| Result: | Showed a significant increase in survival compared with controls. |